SCM Lifescience
Overview
SCM Lifescience is a publicly traded South Korean biopharmaceutical company that develops stem cell therapeutics for a variety of immune-related and incurable diseases using its proprietary subfractionation culturing method. The company's strategy includes 'open innovation', where it expands its pipeline through strategic equity investments, joint ventures, and acquisitions of other biotechnology firms. It also provides CMO services for stem cell production.
Portfolio Companies
2
Website
scmlifescience.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Vita Therapeutics | Jun 2021 | Series A | Co-investor |
| CoImmune, Inc. | Nov 2020 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is SCM Lifescience based?
SCM Lifescience is headquartered in Incheon, Incheon, South Korea.
When was SCM Lifescience founded?
Founding year information for SCM Lifescience is not publicly available.
How many portfolio companies does SCM Lifescience have?
SCM Lifescience has 2 portfolio companies in Caplight's dataset.
What are some companies in SCM Lifescience's portfolio?
Portfolio companies visible on Caplight include Vita Therapeutics, CoImmune, Inc..
What was SCM Lifescience's most recent investment shown here?
SCM Lifescience's most recent investment in this portfolio sample was in Vita Therapeutics in 2021.
What sectors does SCM Lifescience focus on?
SCM Lifescience focuses on Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does SCM Lifescience focus on?
SCM Lifescience typically invests at the Early stage.